RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionONCY has $500 million in R&D write-offs and the potential of $US 2.4 Billion in peak annual sales, according to ONCY's presentation but much higher by an estimated 2x+ more from global reports, for the 3rd line HR+/HER2- breast cancer alone that pelareorep is expectedto address, and with 13 years of FDA market exclusivity from the approval date of pelareorep.
And then there are 2 indications in PDAC, which would be valued at an estimated several billion dollars more, followed by anal cancer, TNBC, CRC and GI cancer indications as follow-on approvals